Almost half of the healthcare economic burden associated with vaccine preventable diseases are attributable to older adults with influenza. Researchers of a study assessed the annualized mean all-cause and influenza-related healthcare costs among individuals aged ≥65 years who are vaccinated with adjuvanted trivalent influenza vaccine (aTIV) and trivalent high-dose influenza vaccine (TIV-HD). The results were published as a poster at the Academy of Managed Care Pharmacy Nexus 2021.
Researchers retrospectively evaluated an Inverse Probability of Treatment Weighting (IPTW) sample consisting of 798,987 recipients of aTIV and 1,655,979 recipients of TIV-HD in the US using professional fee, prescription claims, and hospital charge master data, via IQVIA’s New Data Warehouse. Baseline characteristics analyzed in this study included age, gender, payer type, geographic region, Charlson Comorbidity Index, comorbidities, indicators of frail health status, and pre-index hospitalization rates. Economic outcomes included annualized mean all-cause and influenza-related costs, which comprised influenza-related hospitalizations, emergency room visits, physician office visits, and pharmacy. The study period ended on March 7, 2020 to avoid any misclassification between flu and COVID-19 infection.
Following analysis, the results showed that during the 2019-20 influenza season, the mean annualized all-cause and influenza-related costs (USD) per patient were statistically similar between aTIV and TIV-HD ($13,196 vs. $13,221 and $21.64 vs. $21.92, respectively). Both aTIV and TIV-HD were comparable in terms of predicted mean annualized costs for influenza-related hospitalizations ($22.98 vs. $22.04, respectively) and influenza-related office visits ($2.01 vs. $1.92), the researchers noted.
The authors concluded, “Real-world evidence demonstrated that in the 2019-20 influenza season, aTIV and TIV-HD were associated with similar all-cause and influenza-related total healthcare costs.”
Source: Shah D, et al. Economic Impact of Enhanced Influenza Vaccines on Healthcare Costs for The US Elderly: A Real-World Evaluation of Adjuvanted Trivalent Influenza Vaccine Compared to Trivalent High-Dose Influenza Vaccine for the 2019-20 Influenza Season. Poster J1. Published for AMCP Nexus 2021; October 18-21, 2021, Denver, CO.